Clinical Outcomes of Trimethoprim-Sulfamethoxazole with or Without Adjunctive Caspofungin in Patients with Moderate-to-Severe HIV-Associated Pneumocystis jirovecii Pneumonia: A Retrospective Cohort Study
- 1Department of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, People’s Republic of China
- 2Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, People’s Republic of China
- 3Beijing Research Center for Respiratory Infectious Diseases, Beijing, 100069, People’s Republic of China
Abstract
Purpose: To evaluate clinical outcomes of trimethoprim-sulfamethoxazole (TMP-SMX) with or without adjunctive caspofungin in patients with moderate-to-severe human immunodeficiency virus (HIV)-associated Pneumocystis jirovecii pneumonia (PJP), and explore factors associated with poor outcomes.
Patients and Methods: Patients with HIV-associated PJP admitted to Beijing Youan Hospital from July 2020 to June 2026 were retrospectively included. Moderate-to-severe PJP was defined as arterial partial pressure of oxygen <70 mmHg or alveolar-arterial oxygen gradient ≥35 mmHg on room air. Patients were grouped by regimen: TMP-SMX monotherapy or TMP-SMX plus caspofungin. The primary outcome was a composite of poor outcomes, including in-hospital death or discharge against medical advice due to poor prognosis. Between-group comparisons, a clinically specified multivariable logistic regression model, and a stabilized inverse probability of treatment weighting (IPTW) sensitivity analysis were performed.
Results: Among 673 screened patients, 155 with moderate-to-severe HIV-associated PJP were analyzed after excluding mild cases and those with incomplete data; 78 received TMP-SMX monotherapy and 77 received TMP-SMX plus caspofungin. The combination group had longer hospital stays (P = 0.003) and higher procalcitonin levels (P = 0.044). Poor outcomes did not differ significantly between groups (P = 0.129). In the primary multivariable model adjusted for PaO2 on room air and C-reactive protein (CRP), adjunctive caspofungin was not significantly associated with poor outcome (adjusted odds ratio [aOR] = 1.603, 95% confidence interval [CI]: 0.654–3.925, P = 0.302). Lower PaO2 (aOR = 0.958, 95% CI: 0.921–0.996, P = 0.032) and higher CRP (aOR = 1.009, 95% CI: 1.000–1.019, P = 0.047) were associated with poor outcome. The IPTW sensitivity analysis likewise showed no statistically significant association between adjunctive caspofungin and poor outcome (weighted OR = 1.939, 95% CI: 0.790–4.763, P = 0.148).
Conclusion: In this retrospective cohort, no statistically significant association was detected between TMP-SMX plus adjunctive caspofungin and poor outcomes in patients with moderate-to-severe HIV-associated PJP. Lower PaO2 and higher CRP were associated with poor outcome in an exploratory adjusted analysis. Larger prospective multicenter studies are needed to clarify the role of adjunctive caspofungin.
Related
- Disseminated Trimethoprim/Sulfamethoxazole–Resistant Nocardiosis in Renal Transplant Recipient, India
- Drug-Induced Immune Thrombocytopenia Caused by Sulfamethoxazole-Trimethoprim: A Case Report
- Single-strength trimethoprim/sulfamethoxazole (TMP/SMX)-induced hypoglycaemia in a post kidney-pancreas transplant patient
- Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim–Sulfamethoxazole Resistance in Burkholderia thailandensis
- Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum β-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes
BibTeX
@article{wang2026clinical,
title = {{Clinical Outcomes of Trimethoprim-Sulfamethoxazole with or Without Adjunctive Caspofungin in Patients with Moderate-to-Severe HIV-Associated Pneumocystis jirovecii Pneumonia: A Retrospective Cohort Study}},
author = {Yu Wang and Caopei Zheng and Yuqing Sun and Yulin Zhang},
journal = {Infection and Drug Resistance},
year = {2026},
month = nov,
doi = {10.2147/idr.s638117},
url = {https://doi.org/10.2147/idr.s638117},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Clinical Outcomes of Trimethoprim-Sulfamethoxazole with or Without Adjunctive Caspofungin in Patients with Moderate-to-Severe HIV-Associated Pneumocystis jirovecii Pneumonia: A Retrospective Cohort Study
AU - Yu Wang
AU - Caopei Zheng
AU - Yuqing Sun
AU - Yulin Zhang
PY - 2026
DA - 2026/11/07
JO - Infection and Drug Resistance
DO - 10.2147/idr.s638117
UR - https://doi.org/10.2147/idr.s638117
AB - Purpose: To evaluate clinical outcomes of trimethoprim-sulfamethoxazole (TMP-SMX) with or without adjunctive caspofungin in patients with moderate-to-severe human immunodeficiency virus (HIV)-associated Pneumocystis jirovecii pneumonia (PJP), and explore factors associated with poor outcomes. Patients and Methods: Patients with HIV-associated PJP admitted to Beijing Youan Hospital from July 2020 to June 2026 were retrospectively included. Moderate-to-severe PJP was defined as arterial partial pressure of oxygen <70 mmHg or alveolar-arterial oxygen gradient ≥35 mmHg on room air. Patients were grouped by regimen: TMP-SMX monotherapy or TMP-SMX plus caspofungin. The primary outcome was a composite of poor outcomes, including in-hospital death or discharge against medical advice due to poor prognosis. Between-group comparisons, a clinically specified multivariable logistic regression model, and a stabilized inverse probability of treatment weighting (IPTW) sensitivity analysis were performed. Results: Among 673 screened patients, 155 with moderate-to-severe HIV-associated PJP were analyzed after excluding mild cases and those with incomplete data; 78 received TMP-SMX monotherapy and 77 received TMP-SMX plus caspofungin. The combination group had longer hospital stays (P = 0.003) and higher procalcitonin levels (P = 0.044). Poor outcomes did not differ significantly between groups (P = 0.129). In the primary multivariable model adjusted for PaO2 on room air and C-reactive protein (CRP), adjunctive caspofungin was not significantly associated with poor outcome (adjusted odds ratio [aOR] = 1.603, 95% confidence interval [CI]: 0.654–3.925, P = 0.302). Lower PaO2 (aOR = 0.958, 95% CI: 0.921–0.996, P = 0.032) and higher CRP (aOR = 1.009, 95% CI: 1.000–1.019, P = 0.047) were associated with poor outcome. The IPTW sensitivity analysis likewise showed no statistically significant association between adjunctive caspofungin and poor outcome (weighted OR = 1.939, 95% CI: 0.790–4.763, P = 0.148). Conclusion: In this retrospective cohort, no statistically significant association was detected between TMP-SMX plus adjunctive caspofungin and poor outcomes in patients with moderate-to-severe HIV-associated PJP. Lower PaO2 and higher CRP were associated with poor outcome in an exploratory adjusted analysis. Larger prospective multicenter studies are needed to clarify the role of adjunctive caspofungin.
SN - 1178-6973
ER -